BindingDB logo
myBDB logout

101 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28174066 23 Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRFEBI Takeda Pharmaceutical Company Ltd.
27894044 37 An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.EBI University of KwaZulu-Natal
26901666 26 Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.EBI Takeda Pharmaceutical Company Ltd.
26789203 100 Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).EBI Salk Institute
26456805 27 Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors.EBI Emory University
22381334 2 In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.EBI Bristol-Myers Squibb Co.
24675175 5 Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.EBI South Dakota State University
23465610 16 Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.EBI Bristol-Myers Squibb Research and Development
17629700 18 Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists.EBI GlaxoSmithkline
16134945 1 Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.EBI Neurocrine Biosciences
22587443 55 Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.EBI Eisai Co., Ltd.
21074436 17 Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.EBI Neurocrine Biosciences
18975927 44 Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.EBI GlaxoSmithKline Medicines Research Centre
18989952 23 Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.EBI GlaxoSmithKline Medicines Research Centre
22971011 26 Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.EBI Eisai Co., Ltd.
23010264 14 [18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.EBI Bristol-Myers Squibb Co.
23062820 41 Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.EBI Eisai Co., Ltd
22871582 29 Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF1 receptor antagonists.EBI Eisai Co., Ltd
22749422 43 Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.EBI Bristol-Myers Squibb Co
22683343 27 Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.EBI Eisai Co., Ltd
20408551 13 Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).EBI Westfalische Wilhelms-Universitat
19552436 43 In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI Bristol-Myers Squibb Company
18672365 33 2-Arylpyrimidines: novel CRF-1 receptor antagonists.EBI Neurogen Corporation
15743196 40 Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.EBI Neurocrine Biosciences Inc.
15943483 21 Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.EBI Neurocrine Biosciences
12904058 2 Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.EBI National Institutes of Health
12361401 60 Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.EBI Salk Institute
10794681 43 Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.EBI DuPont Pharmaceuticals Company
10669572 14 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.EBI DuPont Pharmaceuticals Company
10072680 32 Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.EBI DuPont Pharmaceuticals Company
22196514 70 Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF¿?) receptor antagonists.EBI Minase Research Institute
22104142 9 Lead diversification. Application to existing drug molecules: mifepristone 1 and antalarmin 8.EBI Pfizer Inc.
21889333 30 Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.EBI Pfizer Inc.
21930387 60 Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF¿?) receptor antagonists.EBI Minase Research Institute
21865047 48 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.EBI Minase Research Institute
21618986 65 Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.EBI Neurogen Corporation
21295475 21 Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.EBI Pfizer Inc.
21414781 16 Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.EBI Takeda Pharmaceutical Company Ltd
21411322 8 Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines.EBI Bristol-Myers Squibb Research and Development
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20483614 56 5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists.EBI Bristol-Myers Squibb Research and Development
20471832 60 Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
20185312 34 Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).EBI Bristol-Myers Squibb Research& Development
20176478 26 Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI Bristol-Myers Squibb Company
19782566 30 Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.EBI Pfizer Global Research and Development
19954247 17 A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.EBI Bristol-Myers Squibb Company
19552437 50 Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI Bristol-Myers Squibb Company
18180159 32 The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.EBI Neurogen Corporation
17888659 62 Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.EBI Pfizer Global Research and Development
17258456 41 An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.EBI Pharmaceutical Research Institute
16297619 24 Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.EBI Pharmaceutical Research Institute
16078829 26 Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.EBI Neurocrine Biosciences Inc.
15990298 43 Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.EBI Pharmaceutical Research Institute
15982881 44 Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.EBI Pharmaceutical Research Institute
15634020 110 Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.EBI Procter & Gamble Pharmaceuticals
15603967 49 Optimization of CRF1R binding affinity of 2-(2,4,6-trichlorophenyl)-4-trifluoromethyl-5-aminomethylthiazoles through rapid and selective parallel synthesis.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15509177 27 Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15341493 45 Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.EBI Neurocrine Biosciences, Inc.
15341489 34 Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.EBI Pharmaceutical Research Institute
15225703 37 Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.EBI Neurocrine Biosciences, Inc.
15225687 34 Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.EBI Neurocrine Bioscience, Inc.
15203140 28 Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.EBI Neurocrine Biosciences, Inc.
15115386 43 N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.EBI Bristol-Myers Squibb Pharma Research Laboratories
15080983 20 Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.EBI Neurocrine Biosciences, Inc
14971886 21 New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.EBI Central Pharmaceutical Research Institute
14592493 30 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12951129 30 Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.EBI Neurocrine Biosciences, Inc.
12951128 51 Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists.EBI Neurocrine Biosciences, Inc.
12951127 32 Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists.EBI Neurocrine Biosciences, Inc.
12852951 21 2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel crf-1 receptor antagonists.EBI Neurogen Corporation
12127521 33 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.EBI Neurogen Corporation
12014949 63 Arylamidrazones as novel corticotropin releasing factor receptor antagonists.EBI TBA
11720866 19 1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF(1)) receptor antagonist activities.EBI Neurocrine Biosciences, Inc.
11212103 4 The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type.EBI NIDDK
10782669 7 Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor.EBI NIDDK
10395475 20 Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity.EBI The University of Wollongong
10328310 15 Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.EBI DuPont Pharmaceuticals Company
10230641 14 Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists.EBI DuPont Pharmaceuticals Company
10230640 33 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists.EBI DuPont Pharmaceuticals Company
10230622 25 Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.EBI DuPont Pharmaceuticals Company
10201844 24 Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists.EBI A Subsidiary of Agouron Pharmaceuticals, Inc.
10072681 113 Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.EBI DuPont Pharmaceuticals Company
10072679 86 Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.EBI DuPont Pharmaceuticals Company
9873487 14 Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.EBI Warner-Lambert Company
9171885 7 Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.EBI Pfizer Inc.
8893829 13 Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.EBI Neurocrine Biosciences
8893828 28 Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists.EBI Neurocrine Biosciences
15831442 46 Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB Taisho Pharmaceutical Co., Ltd
12649353 15 Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.BDB Bristol-Myers Squibb Pharmaceuticals Research Institute
12538838 14 Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.BDB Taisho Pharmaceutical Co.
11907190 4 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.BDB Sanofi-Synthelabo
11750183 29 Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.BDB Novartis Pharma
10215672 11 Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.BDB Taisho Pharmaceutical Co., Ltd.
19361209 30 Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.BDB Bristol-Myers Squibb Company
19361210 44 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.BDB Bristol-Myers Squibb Company
17402721 20 Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.BDB Bristol-Myers Squibb Company
18288792 8 2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists.BDB Pfizer
18260619 33 Synthesis and SAR of 2-Aryloxy-4-alkoxy-pyridines as Potent Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists.BDB Pfizer